文献速递乳腺骨肌技术与安全MRCTPET

全身MRI、CT与骨闪烁显像在转移性乳腺癌骨转移抗癌治疗反应评估中的比较

Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone.
PubMed 文献 · Radiology · 2020-10-20

这项前瞻性研究纳入45例骨-only转移性乳腺癌患者,在全身系统抗癌治疗期间每12周行CT和全身MRI,必要时行骨闪烁显像,由放射科医师独立盲法判读。结果显示,在33例影像学进展的患者中,67%仅全身MRI发现进展,33%为CT与全身MRI同时发现,无仅CT发现进展者(P<.001)。

要点

  • 骨-only转移性乳腺癌治疗随访中,全身MRI可比CT更早发现进展,67%的进展仅由全身MRI显示。
  • CT与全身MRI对进展的判读一致性仅为轻微(Cohen κ=0.15)。
  • 骨闪烁显像仅在50%的骨进展患者中报告进展,与CT和/或全身MRI的骨进展不一致(P<.001)。

关键影像表现/征象

  • 在33例影像学进展患者中,67%(22例)仅全身MRI发现进展,33%(11例)CT与全身MRI同时发现进展,无仅CT发现进展者(P<.001,McNemar检验)。
  • 全身MRI与CT判读进展的一致性仅为轻微(Cohen κ=0.15)。
  • 在CT和/或全身MRI显示骨进展的26例患者中,50%(13例)骨闪烁显像报告进展(P<.001,McNemar检验)。

局限性

  • 2例因基线全身MRI明确显示肝转移被排除,2例因影像显示进展前出现临床进展被排除,1例失访。
  • 中位研究时间36周(范围1-120周)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background CT and bone scintigraphy have limitations in evaluating systemic anticancer therapy (SACT) response in bone metastases from metastatic breast cancer (MBC). Purpose To evaluate whether whole-body MRI enables identification of progressive disease (PD) earlier than CT and bone scintigraphy in bone-only MBC. Materials and Methods This prospective study evaluated participants with bone-only MBC between May 2016 and January 2019 (ClinicalTrials.gov identifier: NCT03266744). Participants were enrolled at initiation of first or subsequent SACT based on standard CT and bone scintigraphy imaging. Baseline whole-body MRI was performed within 2 weeks of entry; those with extraosseous disease were excluded. CT and whole-body MRI were performed every 12 weeks until definitive PD was evident with one or both modalities. In case of PD, bone scintigraphy was used to assess for bone disease progression. Radiologists independently interpreted images from CT, whole-body MRI, or bone scintigraphy and were blinded to results with the other modalities. Systematic differences in performance between modalities were analyzed by using the McNemar test. Results Forty-five participants (mean age, 60 years ± 13 [standard deviation]; all women) were evaluated. Median time on study was 36 weeks (range, 1-120 weeks). Two participants were excluded because of unequivocal evidence of liver metastases at baseline whole-body MRI, two participants were excluded because they had clinical progression before imaging showed PD, and one participant was lost to follow-up. Of the 33 participants with PD at imaging, 67% (22 participants) had PD evident at whole-body MRI only and 33% (11 participants) had PD at CT and whole-body MRI concurrently; none had PD at CT only (P < .001, McNemar test). There was only slight agreement between whole-body MRI and CT (Cohen κ, 0.15). PD at bone scintigraphy was reported in 50% of participants (13 of 26) with bone progression at CT and/or whole-body MRI (P < .001, McNemar test). Conclusion Whole-body MRI enabled identification of progressive disease before CT in most participants with bone-only metastatic breast cancer. Progressive disease at bone scintigraphy was evident in only half of participants with bone progression at whole-body MRI. © RSNA, 2020 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Kosmin M, Padhani AR, Gogbashian A, et al. Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone. Radiology. 2020. PMID: 33078998. doi:10.1148/radiol.2020192683

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。